Patients with D2T-PsA can be stratified into inflammatory and noninflammatory phenotypes, with the former linked to higher sonographic activity.

Patients with PsA have a higher prevalence of MetS compared with members of the general population and individuals with other inflammatory arthropathies.

A subset of patients with PsA achieved rapid and sustained remission following treatment with b/tsDMARDs and were classified as a super-responder phenotype.

Recently, researchers in Australia tested baricitinib, a drug used for rheumatoid arthritis, in people newly diagnosed with Type‑1 diabetes, showing promising results for early intervention.

Research team from the universities of Southampton and Keele, working alongside the NHS and Versus Arthritis A new project ...

The FDA approved a supplemental new drug application for Tremfya for the treatment of children aged 6 years or older with ...

Guselkumab is the first IL-23 inhibitor approved for pediatric plaque psoriasis and active psoriatic arthritis, addressing a significant treatment gap. The PROTOSTAR study showed 56% of children on ...

High-intensity exercise has a beneficial effect on fatigue and improves quality of life in patients with rheumatoid arthritis ...

Back pain is rarely “just back pain.” Research shows it often comes with heart disease, arthritis, depression, or other chronic illnesses.

Osteoarthritis affects about ten million Britons. From diet swaps to supplements that work and exercises to ease the agony, ...

Objectives C reactive protein (CRP) is frequently normal in psoriatic arthritis (PsA) despite active disease, complicating ...

Objective Breastfeeding prevalence and challenges among women of systemic lupus erythematosus (SLE) and rheumatoid arthritis ...